Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for Medical World News®, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.
He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on LinkedIn.
Improved Sense of Smell Achieved With Biologics for CRS With Nasal Polyps, Asthma
May 12th 2022Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and severe asthma reported significant improvement in their sense of smell when treated with the biologics omalizumab, mepolizumab, reslizumab, or benralizumab, with no significant differences observed between the treatment groups.
Read More
Study Finds Bimekizumab Well Tolerated Long Term for Moderate to Severe Psoriasis
May 11th 2022Bimekizumab demonstrated a favorable long-term safety profile for the treatment of moderate to severe psoriasis, aside from an increased incidence of mild to moderate oral candidiasis that was also observed with short-term exposure.
Read More
Study Shows Caregivers Prefer Dermatology Specialists Over PCPs for Pediatric Atopic Dermatitis
May 10th 2022Dermatology specialists were cited by diverse caregivers of children with atopic dermatitis (AD) to provide enhanced care delivery and improved AD disease control compared with primary care providers.
Read More
Taking Action Against the Rising Mental Health Crisis: Efforts From Health Plans, Congress, and More
May 10th 2022Marking Mental Health Awareness month, stakeholders involved in the delivery of behavioral health care services discuss current efforts underway—spearheaded by the novel 988 emergency hotline—to address the growing mental health crisis.
Read More
Dr Elaine Siegfried on Safety Considerations for JAK Inhibitors in Pediatric Atopic Dermatitis
May 6th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on safety considerations for the use of Janus kinase (JAK) inhibitors in pediatric patients with atopic dermatitis.
Read More
Machine Learning Identifies Predictors of Revision Endoscopic Sinus Surgery
May 5th 2022A machine learning approach identified age and several comorbidities, such as nasal polyps and asthma, as being associated with revision endoscopic sinus surgery among patients with chronic rhinosinusitis.
Read More
Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis
May 5th 2022An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.
Read More
High Disability Burden of Atopic Dermatitis Linked With Socioeconomic Status
May 4th 2022Atopic dermatitis was associated with the greatest burden of disease compared with 2 other types of dermatitis, in which high incidence and disability-adjusted life-years rates corresponded with high sociodemographic index areas.
Read More
Clinical Improvement of AERD Achieved With Dupilumab Use for Asthma, CRS With Nasal Polyps
May 3rd 2022Patients with aspirin-exacerbated respiratory disease (AERD) who initiated treatment with dupilumab as an add-on asthma or chronic rhinosinusitis with nasal polyps therapy reported rapid clinical improvement that was sustained after 3 months.
Read More
Cardiovascular Risk Significantly Greater in Patients With Psoriatic Disease
May 2nd 2022A significantly greater risk of cardiovascular events was observed among a multiethnic Brazilian population of patients with psoriasis and psoriatic arthritis vs controls, in which those in the sixth decade of life had the highest risk.
Read More
HPV Infection May Increase Risk of Developing CRS With Nasal Polyps
April 30th 2022Presence of human papillomavirus (HPV) was significantly associated with incidence of chronic rhinosinusitis with nasal polyps (CRSwNP), although no differences in disease severity were observed among HPV-positive and HPV-negative patients with CRSwNP.
Read More
Real-world Patients Show Significant Improvement With Dupilumab for CRS With Nasal Polyps
April 28th 2022Use of dupilumab was associated with significant improvement in clinical symptoms of chronic rhinosinusitis (CRS) with nasal polyps among real-world patients in Canada, with benefits shown to be similar to that observed in randomized clinical trials.
Read More
Dr Robert Sidbury on Mental Health Implications of Atopic Dermatitis
April 28th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on the mental health comorbidity risk linked with atopic dermatitis and how dermatologists can play a role in managing behavioral care needs of at-risk patients.
Read More
Nathan H. Walcker on Expectations for Stakeholders Attending Tampa IVBM Meeting
April 27th 2022Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.
Read More
Dr Michael Diaz Previews In-person Tampa IVBM Meeting
April 26th 2022Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, previews the Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), cohosted by Florida Cancer Specialists & Research Institute.
Read More
Surveyed Patients Identify Unmet Needs in CRS With Nasal Polyps
April 23rd 2022Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack of public and physician awareness on disease burden and poor sleep quality.
Read More
Dr Stephen Rozzo Discusses Real-world Efficacy of Tildrakizumab for Psoriasis
April 22nd 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.
Read More
Dr Elaine Siegfried on Considerations for Systemic Therapy Use in Pediatric Atopic Dermatitis
April 20th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.
Read More
Ixekizumab Effective Long-term for Treatment of Psoriasis in Pediatric Patients
April 20th 2022Pediatric patients with psoriasis exhibited significant improvements in self-reported outcomes and objective measures of complete skin clearance when treated with ixekizumab vs placebo, with no new safety findings identified.
Read More
Spotlighting Health-, Cost-Related Benefits of Genomic Testing and How Employers Can Drive Adoption
April 20th 2022Key opinion leaders addressed cost, accessibility, and other barriers limiting use of comprehensive genomic profiling (CGP), and how employers can help drive preventive care and precision medicine through CGP.
Read More
Dr Stephen Schleicher Previews Nashville IVBM Meeting
April 18th 2022Stephen M. Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, previews the Nashville meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by Tennessee Oncology.
Read More
Dr Davey Daniel on Barriers Limiting Genomic Testing Use in Lung Cancer
April 17th 2022Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.
Read More
Dr Stephen Rozzo Explains Real-world Study Design for Tildrakizumab in Psoriasis
April 15th 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, spoke on the design of the 2 phase 4 real-world studies investigating severity and quality of life impact of tildrakizumab for the treatment of psoriasis.
Read More